Impact of time to treatment on the effects of bivalirudin vs. glycoprotein IIb/IIIa inhibitors and heparin in patients undergoing primary percutaneous coronary intervention: insights from the HORIZONS-AMI trial

EuroIntervention 2016;12:1144-1153. DOI: 10.4244/EIJV12I9A186

Mikkel Schoos
Mikkel M. Schoos1,2, MD, PhD; Giuseppe De Luca3, MD, PhD; George D. Dangas1,4, MD, PhD; Peter Clemmensen5, MD, DMSc; Girma Minalu Ayele4, PhD; Roxana Mehran1,4, MD; Gregg W. Stone4,6*, MD
1. Mount Sinai Medical Center, New York, NY, USA; 2. Department of Cardiology, Zealand University Hospital, Roskilde, Denmark; 3. Division of Cardiology, Ospedale Maggiore della Carità, Eastern Piedmont University, Novara, Italy; 4. Cardiovascular Researc

Aims: In the HORIZONS-AMI trial, bivalirudin compared to unfractionated heparin (UFH) plus a glycoprotein IIb/IIIa inhibitor (GPI) improved net clinical outcomes in patients undergoing pr

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

percutaneous coronary interventionreperfusion timest-segment elevation myocardial infarction
Coronary interventionsSTEMIAdjunctive pharmacotherapy
Read next article
Assessing the cardiology community position on transradial intervention and the use of bivalirudin in patients with acute coronary syndrome undergoing invasive management: results of an EAPCI survey

Latest news